DEVELOPMENT AND EVALUATION OF ENTARIC COATED RABEPARAZOLE SODIUM 50 MG TABLET FOR ENHANCE GASTRO RESISTANCE AND STABILITY

Pharmacy

Rabeprazole sodium is a proton pump inhibitor that works by blocking the acidic pump enzyme H+ /K+ATPase, which is used to treat peptic ulcers, duodenal ulcers, and gastro-oesophageal reflux disease. Additionally, it is used to treat erosive esophagitis and Zollinger-Ellison syndrome. The goal of this research is to create enteric-coated tablets of Rabeprazole sodium that are stable and pharmaceutically equal to the original product. The goal of the current work is to prevent drug breakdown in the stomach's acidic environment. Mannitol as diluents, magnesium stearate and talc as lubricants and glidants, ethyl cellulose as a seal coating, Eudragit L-30, Plasacrylic HTP, and Instacoat EN HPMC Pthalate as an enteric coating were used to create ten different formulations of Rabeprazole core tablets. F9 outperformed the innovator in terms of drug release profile among the 10 batches of uncoated tablets. As a result, batch F9 was chosen for enteric coating and subcoating, two additional formulation stages. Following enteric coating, batches F9 were assessed for acid resistance and in vitro dissolving tests, and they were deemed to be appropriate for Rabeprazole sodium delayed release tablets when compared to innovator. For a duration of three months, stability assessments were performed at 40°C with 75% relative humidity.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.